Hola,
Are you new here?

PREVENTROP

financed

New approach to treatment of the blinding disease Retinopathy of Prematurity RO...

New approach to treatment of the blinding disease Retinopathy of Prematurity ROP The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical stu... see more

30/09/2018

UGOT - GOETEBORGS...

8M€

Project Budget: 8M€

Project leader

GOETEBORGS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 11 Participantes

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2018-09-30 We do not have the information of the call

0% 79% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

UGOT - GOETEBORGS UNIVERSITE...

0.00€ | Leader

Academisch Medisch Centrum A...

N.D. | participant

SMERUD

N.D. | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

GOETEBORGS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 8M€

participation deadline Sin fecha límite de participación.

Project description The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated orphan medicinal product. This orphan medicinal product has been granted the EU orphan designation. We have completed both a Phase I study and the first section of the Phase II study administering the growth factor complex IGF-I/IGFBP-3 (Premiplex®) successfully to preterm infants in order to prevent ROP– a discovery that we have taken from bench to bedside. Due to improved neonatal care, the survival of preterm babies has increased dramatically during the last decades. The downside of this improvement in survival rates is higher morbidity affecting these vulnerable infants. It should be emphasised that in a preterm infant any lasting morbidity will have a negative impact on the quality of life for a whole life span for both the individual and their families. One of the most severe morbidities affecting these infants is retinopathy causing severe visual impairment and blindness. Our research findings have rendered several editorials pointing at the hope of prevention strategies which if successful will change the paradigm for ROP and other morbidities in preterm infants. There are three major impacts of the present proposal; (1) clinical availability of a new orphan designated drug product, Premiplex®, and (2) improved care of preterm infants and (3) a significant contribution towards the goal of the International Rare Disease Research Consortium (IRDiRC) by delivering one new therapy for a rare disease.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers